|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Rivaroxaban#Adult Indications and Dosage]] |
| {{Rivaroxaban}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| == Indications and Usage==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| === Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation===
| |
| XARELTO is indicated to reduce the risk of [[stroke]] and systemic embolism in patients with nonvalvular [[atrial fibrillation]].
| |
| | |
| There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see [[Rivaroxaban clinical studies|Clinical Studies (14.1)]]].
| |
| | |
| | |
| === Treatment of Deep Vein Thrombosis===
| |
| XARELTO is indicated for the treatment of [[deep vein thrombosis]] (DVT).
| |
| | |
| | |
| === Treatment of Pulmonary Embolism===
| |
| XARELTO is indicated for the treatment of [[pulmonary embolism]] (PE).
| |
| | |
| | |
| === Reduction in the Risk of Recurrence of Deep Vein Thrombosis and of Pulmonary Embolism===
| |
| XARELTO is indicated for the reduction in the risk of recurrence of [[deep vein thrombosis]] and of [[pulmonary embolism]] following initial 6 months treatment for DVT and/or PE.
| |
| | |
| | |
| === Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery===
| |
| XARELTO is indicated for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = XARELTO (RIVAROXABAN) TABLET, FILM COATED [JANSSEN PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]] | |